NEW YORK (GenomeWeb) – Cantor Fitzgerald today downgraded PerkinElmer to Neutral from Overweight, but maintained the stock's $60 price target, citing a positive long-term outlook and caution in the near term.
Registering provides access to this and other free content.
Already have an account?Login Now.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.